In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India Article Swipe
Kalyani Borde
,
M. Abdul Kareem
,
Ratna Mani Sharma
,
S. Manick Dass
,
Vedantham Ravi
,
Dilip Mathai
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1128/spectrum.00847-23
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1128/spectrum.00847-23
Cefiderocol (FDC), a novel siderophore drug, is active against Gram-negative bacteria producing carbapenemases, including metallo-beta-lactamases. The objective of this study is to compare the in vitro activity of FDC with ceftazidime-avibactam (CZA), CZA/aztreonam (AT) combination, and colistin (CST), in clinical isolates of meropenem-resistant (MER-R) Klebsiella pneumoniae . From the 2,052 clinical specimens submitted for culture testing, 245 K . pneumoniae isolates were recovered within a 6-month period in 2021. One hundred three non-duplicate, non-outbreak, MER-R (minimum inhibitory concentration, MIC >4 µg/mL) strains were included in the study. Identification and susceptibility were performed using VITEK-2 (bioMérieux). Meropenem-susceptible isolates ( n = 10) served as controls. For FDC, broth microdilution (BMD) was performed after in-house standardization. Disk diffusion (Liofilchem, Italy) and broth microdilution (ComASP, STC, Liofilchem, Italy) were used for susceptibility testing of CZA and CST, respectively. Synergy testing for CZA and AT was performed using disk approximation method. CLSI breakpoints were used for the interpretation of the results. For FDC, MIC 50 and MIC 90 were 2 and 8 µg/mL, respectively. A total of 80% of isolates were susceptible to FDC, 26.2% of isolates were susceptible to CZA, synergy testing with CZA/AT was positive for 74 (72%) of the isolates, and 89.3% were intermediate to CST. Nine (8.7%) were susceptible only to FDC. FDC is active in vitro against MER-R K. pneumoniae >CZA/AT > CZA > CST , as observed in this study, applying CLSI criteria. Clinico-microbiological studies should be performed to assess the clinical efficacy of this novel drug in this region with a high prevalence of carbapenem resistance among Gram-negative organisms. Importance Management of infections with multi-drug resistant Klebsiella pneumoniae is a major challenge in hospital settings, with few treatment options. In this study, the authors aim to assess the in vitro susceptibility of these clinical isolates to cefiderocol, a novel siderophore. Comparators are colistin, ceftazidime-avibactam, and ceftazidime-avibactam/aztreonam synergy, which are currently available options for treatment in this region. Baseline-resistance rates against cefiderocol are higher than those in the previously published studies, with MIC50 and MIC90 at 2 and 8 µg/mL, respectively.
Related Topics
Concepts
Ceftazidime/avibactam
Klebsiella pneumoniae
Aztreonam
Broth microdilution
Microbiology
Ceftazidime
Avibactam
Meropenem
Colistin
Biology
Minimum inhibitory concentration
Antimicrobial
Pseudomonas aeruginosa
Antibiotics
Imipenem
Bacteria
Antibiotic resistance
Escherichia coli
Gene
Genetics
Biochemistry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1128/spectrum.00847-23
- OA Status
- gold
- Cited By
- 6
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4386944331
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4386944331Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1128/spectrum.00847-23Digital Object Identifier
- Title
-
In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from IndiaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-09-22Full publication date if available
- Authors
-
Kalyani Borde, M. Abdul Kareem, Ratna Mani Sharma, S. Manick Dass, Vedantham Ravi, Dilip MathaiList of authors in order
- Landing page
-
https://doi.org/10.1128/spectrum.00847-23Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1128/spectrum.00847-23Direct OA link when available
- Concepts
-
Ceftazidime/avibactam, Klebsiella pneumoniae, Aztreonam, Broth microdilution, Microbiology, Ceftazidime, Avibactam, Meropenem, Colistin, Biology, Minimum inhibitory concentration, Antimicrobial, Pseudomonas aeruginosa, Antibiotics, Imipenem, Bacteria, Antibiotic resistance, Escherichia coli, Gene, Genetics, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
6Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 3Per-year citation counts (last 5 years)
- References (count)
-
25Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4386944331 |
|---|---|
| doi | https://doi.org/10.1128/spectrum.00847-23 |
| ids.doi | https://doi.org/10.1128/spectrum.00847-23 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/37737637 |
| ids.openalex | https://openalex.org/W4386944331 |
| fwci | 0.9640333 |
| type | article |
| title | In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India |
| biblio.issue | 5 |
| biblio.volume | 11 |
| biblio.last_page | e0084723 |
| biblio.first_page | e0084723 |
| topics[0].id | https://openalex.org/T10147 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1313 |
| topics[0].subfield.display_name | Molecular Medicine |
| topics[0].display_name | Antibiotic Resistance in Bacteria |
| topics[1].id | https://openalex.org/T11036 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9995999932289124 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2736 |
| topics[1].subfield.display_name | Pharmacology |
| topics[1].display_name | Antibiotics Pharmacokinetics and Efficacy |
| topics[2].id | https://openalex.org/T10897 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.998199999332428 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2402 |
| topics[2].subfield.display_name | Applied Microbiology and Biotechnology |
| topics[2].display_name | Antibiotic Use and Resistance |
| is_xpac | False |
| apc_list.value | 2500 |
| apc_list.currency | USD |
| apc_list.value_usd | 2500 |
| apc_paid.value | 2500 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2500 |
| concepts[0].id | https://openalex.org/C2775933652 |
| concepts[0].level | 5 |
| concepts[0].score | 0.8239471912384033 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q15410251 |
| concepts[0].display_name | Ceftazidime/avibactam |
| concepts[1].id | https://openalex.org/C2777058267 |
| concepts[1].level | 4 |
| concepts[1].score | 0.798852801322937 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q132592 |
| concepts[1].display_name | Klebsiella pneumoniae |
| concepts[2].id | https://openalex.org/C2780416669 |
| concepts[2].level | 5 |
| concepts[2].score | 0.7892650365829468 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q418546 |
| concepts[2].display_name | Aztreonam |
| concepts[3].id | https://openalex.org/C2780950330 |
| concepts[3].level | 4 |
| concepts[3].score | 0.7545726895332336 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q19903614 |
| concepts[3].display_name | Broth microdilution |
| concepts[4].id | https://openalex.org/C89423630 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6964754462242126 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[4].display_name | Microbiology |
| concepts[5].id | https://openalex.org/C2776968632 |
| concepts[5].level | 4 |
| concepts[5].score | 0.6345094442367554 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q808845 |
| concepts[5].display_name | Ceftazidime |
| concepts[6].id | https://openalex.org/C2777406300 |
| concepts[6].level | 5 |
| concepts[6].score | 0.5598585605621338 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q15410251 |
| concepts[6].display_name | Avibactam |
| concepts[7].id | https://openalex.org/C2779375183 |
| concepts[7].level | 4 |
| concepts[7].score | 0.5229247808456421 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q421670 |
| concepts[7].display_name | Meropenem |
| concepts[8].id | https://openalex.org/C2779259085 |
| concepts[8].level | 3 |
| concepts[8].score | 0.49700406193733215 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q418946 |
| concepts[8].display_name | Colistin |
| concepts[9].id | https://openalex.org/C86803240 |
| concepts[9].level | 0 |
| concepts[9].score | 0.406800776720047 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[9].display_name | Biology |
| concepts[10].id | https://openalex.org/C176947019 |
| concepts[10].level | 3 |
| concepts[10].score | 0.30263036489486694 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q597889 |
| concepts[10].display_name | Minimum inhibitory concentration |
| concepts[11].id | https://openalex.org/C4937899 |
| concepts[11].level | 2 |
| concepts[11].score | 0.21312612295150757 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q68541106 |
| concepts[11].display_name | Antimicrobial |
| concepts[12].id | https://openalex.org/C2777637488 |
| concepts[12].level | 3 |
| concepts[12].score | 0.1951574683189392 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q31856 |
| concepts[12].display_name | Pseudomonas aeruginosa |
| concepts[13].id | https://openalex.org/C501593827 |
| concepts[13].level | 2 |
| concepts[13].score | 0.18908727169036865 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[13].display_name | Antibiotics |
| concepts[14].id | https://openalex.org/C2779631663 |
| concepts[14].level | 4 |
| concepts[14].score | 0.16771504282951355 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q425152 |
| concepts[14].display_name | Imipenem |
| concepts[15].id | https://openalex.org/C523546767 |
| concepts[15].level | 2 |
| concepts[15].score | 0.14233899116516113 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q10876 |
| concepts[15].display_name | Bacteria |
| concepts[16].id | https://openalex.org/C94665300 |
| concepts[16].level | 3 |
| concepts[16].score | 0.10733625292778015 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q63391344 |
| concepts[16].display_name | Antibiotic resistance |
| concepts[17].id | https://openalex.org/C547475151 |
| concepts[17].level | 3 |
| concepts[17].score | 0.06742948293685913 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q25419 |
| concepts[17].display_name | Escherichia coli |
| concepts[18].id | https://openalex.org/C104317684 |
| concepts[18].level | 2 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[18].display_name | Gene |
| concepts[19].id | https://openalex.org/C54355233 |
| concepts[19].level | 1 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[19].display_name | Genetics |
| concepts[20].id | https://openalex.org/C55493867 |
| concepts[20].level | 1 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[20].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/ceftazidime/avibactam |
| keywords[0].score | 0.8239471912384033 |
| keywords[0].display_name | Ceftazidime/avibactam |
| keywords[1].id | https://openalex.org/keywords/klebsiella-pneumoniae |
| keywords[1].score | 0.798852801322937 |
| keywords[1].display_name | Klebsiella pneumoniae |
| keywords[2].id | https://openalex.org/keywords/aztreonam |
| keywords[2].score | 0.7892650365829468 |
| keywords[2].display_name | Aztreonam |
| keywords[3].id | https://openalex.org/keywords/broth-microdilution |
| keywords[3].score | 0.7545726895332336 |
| keywords[3].display_name | Broth microdilution |
| keywords[4].id | https://openalex.org/keywords/microbiology |
| keywords[4].score | 0.6964754462242126 |
| keywords[4].display_name | Microbiology |
| keywords[5].id | https://openalex.org/keywords/ceftazidime |
| keywords[5].score | 0.6345094442367554 |
| keywords[5].display_name | Ceftazidime |
| keywords[6].id | https://openalex.org/keywords/avibactam |
| keywords[6].score | 0.5598585605621338 |
| keywords[6].display_name | Avibactam |
| keywords[7].id | https://openalex.org/keywords/meropenem |
| keywords[7].score | 0.5229247808456421 |
| keywords[7].display_name | Meropenem |
| keywords[8].id | https://openalex.org/keywords/colistin |
| keywords[8].score | 0.49700406193733215 |
| keywords[8].display_name | Colistin |
| keywords[9].id | https://openalex.org/keywords/biology |
| keywords[9].score | 0.406800776720047 |
| keywords[9].display_name | Biology |
| keywords[10].id | https://openalex.org/keywords/minimum-inhibitory-concentration |
| keywords[10].score | 0.30263036489486694 |
| keywords[10].display_name | Minimum inhibitory concentration |
| keywords[11].id | https://openalex.org/keywords/antimicrobial |
| keywords[11].score | 0.21312612295150757 |
| keywords[11].display_name | Antimicrobial |
| keywords[12].id | https://openalex.org/keywords/pseudomonas-aeruginosa |
| keywords[12].score | 0.1951574683189392 |
| keywords[12].display_name | Pseudomonas aeruginosa |
| keywords[13].id | https://openalex.org/keywords/antibiotics |
| keywords[13].score | 0.18908727169036865 |
| keywords[13].display_name | Antibiotics |
| keywords[14].id | https://openalex.org/keywords/imipenem |
| keywords[14].score | 0.16771504282951355 |
| keywords[14].display_name | Imipenem |
| keywords[15].id | https://openalex.org/keywords/bacteria |
| keywords[15].score | 0.14233899116516113 |
| keywords[15].display_name | Bacteria |
| keywords[16].id | https://openalex.org/keywords/antibiotic-resistance |
| keywords[16].score | 0.10733625292778015 |
| keywords[16].display_name | Antibiotic resistance |
| keywords[17].id | https://openalex.org/keywords/escherichia-coli |
| keywords[17].score | 0.06742948293685913 |
| keywords[17].display_name | Escherichia coli |
| language | en |
| locations[0].id | doi:10.1128/spectrum.00847-23 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764766708 |
| locations[0].source.issn | 2165-0497 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2165-0497 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Microbiology Spectrum |
| locations[0].source.host_organization | https://openalex.org/P4310320263 |
| locations[0].source.host_organization_name | American Society for Microbiology |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320263 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Microbiology Spectrum |
| locations[0].landing_page_url | https://doi.org/10.1128/spectrum.00847-23 |
| locations[1].id | pmid:37737637 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Microbiology spectrum |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/37737637 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10580817 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | cc-by |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10580817/pdf/spectrum.00847-23.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Microbiol Spectr |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10580817 |
| locations[3].id | pmh:oai:doaj.org/article:33c2149f89d14e1d8f586b136d52ebf2 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Microbiology Spectrum, Vol 11, Iss 5 (2023) |
| locations[3].landing_page_url | https://doaj.org/article/33c2149f89d14e1d8f586b136d52ebf2 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5083202807 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3518-6258 |
| authorships[0].author.display_name | Kalyani Borde |
| authorships[0].countries | IN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210118361 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[0].institutions[0].id | https://openalex.org/I4210118361 |
| authorships[0].institutions[0].ror | https://ror.org/02f65mn87 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210118361 |
| authorships[0].institutions[0].country_code | IN |
| authorships[0].institutions[0].display_name | Apollo Institute of Medical Sciences & Research |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kalyani Borde |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[1].author.id | https://openalex.org/A5005114023 |
| authorships[1].author.orcid | https://orcid.org/0009-0002-0803-1197 |
| authorships[1].author.display_name | M. Abdul Kareem |
| authorships[1].countries | IN |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210118361 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[1].institutions[0].id | https://openalex.org/I4210118361 |
| authorships[1].institutions[0].ror | https://ror.org/02f65mn87 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210118361 |
| authorships[1].institutions[0].country_code | IN |
| authorships[1].institutions[0].display_name | Apollo Institute of Medical Sciences & Research |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | M. A. Kareem |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[2].author.id | https://openalex.org/A5069658985 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Ratna Mani Sharma |
| authorships[2].countries | IN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210118361 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[2].institutions[0].id | https://openalex.org/I4210118361 |
| authorships[2].institutions[0].ror | https://ror.org/02f65mn87 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210118361 |
| authorships[2].institutions[0].country_code | IN |
| authorships[2].institutions[0].display_name | Apollo Institute of Medical Sciences & Research |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ratna Mani Sharma |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[3].author.id | https://openalex.org/A5066197648 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | S. Manick Dass |
| authorships[3].countries | IN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210118361 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[3].institutions[0].id | https://openalex.org/I4210118361 |
| authorships[3].institutions[0].ror | https://ror.org/02f65mn87 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210118361 |
| authorships[3].institutions[0].country_code | IN |
| authorships[3].institutions[0].display_name | Apollo Institute of Medical Sciences & Research |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | S. Manick Dass |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[4].author.id | https://openalex.org/A5112863947 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Vedantham Ravi |
| authorships[4].countries | IN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210118361 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[4].institutions[0].id | https://openalex.org/I4210118361 |
| authorships[4].institutions[0].ror | https://ror.org/02f65mn87 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210118361 |
| authorships[4].institutions[0].country_code | IN |
| authorships[4].institutions[0].display_name | Apollo Institute of Medical Sciences & Research |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Vedantham Ravi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Microbiology, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[5].author.id | https://openalex.org/A5110208884 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Dilip Mathai |
| authorships[5].countries | IN |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210118361 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Internal Medicine and Adult Infectious Diseases, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| authorships[5].institutions[0].id | https://openalex.org/I4210118361 |
| authorships[5].institutions[0].ror | https://ror.org/02f65mn87 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210118361 |
| authorships[5].institutions[0].country_code | IN |
| authorships[5].institutions[0].display_name | Apollo Institute of Medical Sciences & Research |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Dilip Mathai |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Internal Medicine and Adult Infectious Diseases, Apollo Institute of Medical Sciences and Research , Hyderabad, India |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1128/spectrum.00847-23 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2023-09-23T00:00:00 |
| display_name | In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10147 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1313 |
| primary_topic.subfield.display_name | Molecular Medicine |
| primary_topic.display_name | Antibiotic Resistance in Bacteria |
| related_works | https://openalex.org/W4200435616, https://openalex.org/W3111122494, https://openalex.org/W3188214322, https://openalex.org/W4384703846, https://openalex.org/W3198229456, https://openalex.org/W4311609200, https://openalex.org/W4286435451, https://openalex.org/W3038811303, https://openalex.org/W2038221176, https://openalex.org/W4353093978 |
| cited_by_count | 6 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1128/spectrum.00847-23 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764766708 |
| best_oa_location.source.issn | 2165-0497 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2165-0497 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Microbiology Spectrum |
| best_oa_location.source.host_organization | https://openalex.org/P4310320263 |
| best_oa_location.source.host_organization_name | American Society for Microbiology |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320263 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Microbiology Spectrum |
| best_oa_location.landing_page_url | https://doi.org/10.1128/spectrum.00847-23 |
| primary_location.id | doi:10.1128/spectrum.00847-23 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764766708 |
| primary_location.source.issn | 2165-0497 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2165-0497 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Microbiology Spectrum |
| primary_location.source.host_organization | https://openalex.org/P4310320263 |
| primary_location.source.host_organization_name | American Society for Microbiology |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320263 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Microbiology Spectrum |
| primary_location.landing_page_url | https://doi.org/10.1128/spectrum.00847-23 |
| publication_date | 2023-09-22 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W2912906332, https://openalex.org/W3094338265, https://openalex.org/W4200250437, https://openalex.org/W2683046555, https://openalex.org/W2770431582, https://openalex.org/W3026777707, https://openalex.org/W3038811303, https://openalex.org/W2766395453, https://openalex.org/W4214865323, https://openalex.org/W3006350968, https://openalex.org/W4308002955, https://openalex.org/W3111205916, https://openalex.org/W2948851625, https://openalex.org/W2725995969, https://openalex.org/W2691524510, https://openalex.org/W2790023881, https://openalex.org/W4220888358, https://openalex.org/W4223436515, https://openalex.org/W3043846578, https://openalex.org/W2729331215, https://openalex.org/W3198667590, https://openalex.org/W3086414386, https://openalex.org/W3045885462, https://openalex.org/W4229066902, https://openalex.org/W26641785 |
| referenced_works_count | 25 |
| abstract_inverted_index.( | 98 |
| abstract_inverted_index., | 227 |
| abstract_inverted_index.. | 47, 59 |
| abstract_inverted_index.2 | 166, 339 |
| abstract_inverted_index.8 | 168, 341 |
| abstract_inverted_index.= | 100 |
| abstract_inverted_index.A | 171 |
| abstract_inverted_index.K | 58 |
| abstract_inverted_index.a | 3, 65, 254, 273, 301 |
| abstract_inverted_index.n | 99 |
| abstract_inverted_index.50 | 161 |
| abstract_inverted_index.74 | 195 |
| abstract_inverted_index.90 | 164 |
| abstract_inverted_index.AT | 141 |
| abstract_inverted_index.In | 283 |
| abstract_inverted_index.K. | 220 |
| abstract_inverted_index.as | 103, 228 |
| abstract_inverted_index.at | 338 |
| abstract_inverted_index.be | 239 |
| abstract_inverted_index.in | 25, 39, 68, 85, 216, 230, 250, 276, 292, 318, 329 |
| abstract_inverted_index.is | 7, 21, 214, 272 |
| abstract_inverted_index.of | 18, 28, 42, 131, 155, 173, 175, 182, 197, 246, 257, 265, 295 |
| abstract_inverted_index.to | 22, 179, 186, 204, 211, 241, 289, 299 |
| abstract_inverted_index.10) | 101 |
| abstract_inverted_index.245 | 57 |
| abstract_inverted_index.80% | 174 |
| abstract_inverted_index.CST | 226 |
| abstract_inverted_index.CZA | 132, 139, 224 |
| abstract_inverted_index.FDC | 29, 213 |
| abstract_inverted_index.For | 105, 158 |
| abstract_inverted_index.MIC | 79, 160, 163 |
| abstract_inverted_index.One | 70 |
| abstract_inverted_index.The | 16 |
| abstract_inverted_index.aim | 288 |
| abstract_inverted_index.and | 36, 89, 119, 133, 140, 162, 167, 200, 308, 336, 340 |
| abstract_inverted_index.are | 305, 312, 325 |
| abstract_inverted_index.few | 280 |
| abstract_inverted_index.for | 54, 128, 138, 152, 194, 316 |
| abstract_inverted_index.the | 24, 49, 86, 153, 156, 198, 243, 286, 291, 330 |
| abstract_inverted_index.was | 110, 142, 192 |
| abstract_inverted_index.> | 223, 225 |
| abstract_inverted_index.(AT) | 34 |
| abstract_inverted_index.CLSI | 148, 234 |
| abstract_inverted_index.CST, | 134 |
| abstract_inverted_index.CST. | 205 |
| abstract_inverted_index.CZA, | 187 |
| abstract_inverted_index.Disk | 115 |
| abstract_inverted_index.FDC, | 106, 159, 180 |
| abstract_inverted_index.FDC. | 212 |
| abstract_inverted_index.From | 48 |
| abstract_inverted_index.Nine | 206 |
| abstract_inverted_index.STC, | 123 |
| abstract_inverted_index.disk | 145 |
| abstract_inverted_index.drug | 249 |
| abstract_inverted_index.high | 255 |
| abstract_inverted_index.only | 210 |
| abstract_inverted_index.than | 327 |
| abstract_inverted_index.this | 19, 231, 247, 251, 284, 319 |
| abstract_inverted_index.used | 127, 151 |
| abstract_inverted_index.were | 62, 83, 91, 126, 150, 165, 177, 184, 202, 208 |
| abstract_inverted_index.with | 30, 190, 253, 267, 279, 334 |
| abstract_inverted_index.>4 | 80 |
| abstract_inverted_index.(72%) | 196 |
| abstract_inverted_index.(BMD) | 109 |
| abstract_inverted_index.2,052 | 50 |
| abstract_inverted_index.2021. | 69 |
| abstract_inverted_index.26.2% | 181 |
| abstract_inverted_index.89.3% | 201 |
| abstract_inverted_index.MER-R | 75, 219 |
| abstract_inverted_index.MIC50 | 335 |
| abstract_inverted_index.MIC90 | 337 |
| abstract_inverted_index.after | 112 |
| abstract_inverted_index.among | 260 |
| abstract_inverted_index.broth | 107, 120 |
| abstract_inverted_index.drug, | 6 |
| abstract_inverted_index.major | 274 |
| abstract_inverted_index.novel | 4, 248, 302 |
| abstract_inverted_index.rates | 322 |
| abstract_inverted_index.study | 20 |
| abstract_inverted_index.these | 296 |
| abstract_inverted_index.those | 328 |
| abstract_inverted_index.three | 72 |
| abstract_inverted_index.total | 172 |
| abstract_inverted_index.using | 93, 144 |
| abstract_inverted_index.vitro | 26, 217, 293 |
| abstract_inverted_index.which | 311 |
| abstract_inverted_index.(8.7%) | 207 |
| abstract_inverted_index.(CST), | 38 |
| abstract_inverted_index.(CZA), | 32 |
| abstract_inverted_index.(FDC), | 2 |
| abstract_inverted_index.CZA/AT | 191 |
| abstract_inverted_index.Italy) | 118, 125 |
| abstract_inverted_index.active | 8, 215 |
| abstract_inverted_index.assess | 242, 290 |
| abstract_inverted_index.higher | 326 |
| abstract_inverted_index.period | 67 |
| abstract_inverted_index.region | 252 |
| abstract_inverted_index.served | 102 |
| abstract_inverted_index.should | 238 |
| abstract_inverted_index.study, | 232, 285 |
| abstract_inverted_index.study. | 87 |
| abstract_inverted_index.within | 64 |
| abstract_inverted_index.(MER-R) | 44 |
| abstract_inverted_index.6-month | 66 |
| abstract_inverted_index.Synergy | 136 |
| abstract_inverted_index.VITEK-2 | 94 |
| abstract_inverted_index.against | 9, 218, 323 |
| abstract_inverted_index.authors | 287 |
| abstract_inverted_index.compare | 23 |
| abstract_inverted_index.culture | 55 |
| abstract_inverted_index.hundred | 71 |
| abstract_inverted_index.method. | 147 |
| abstract_inverted_index.options | 315 |
| abstract_inverted_index.region. | 320 |
| abstract_inverted_index.strains | 82 |
| abstract_inverted_index.studies | 237 |
| abstract_inverted_index.synergy | 188 |
| abstract_inverted_index.testing | 130, 137, 189 |
| abstract_inverted_index.µg/mL) | 81 |
| abstract_inverted_index.µg/mL, | 169, 342 |
| abstract_inverted_index.(ComASP, | 122 |
| abstract_inverted_index.(minimum | 76 |
| abstract_inverted_index.ABSTRACT | 0 |
| abstract_inverted_index.activity | 27 |
| abstract_inverted_index.applying | 233 |
| abstract_inverted_index.bacteria | 11 |
| abstract_inverted_index.clinical | 40, 51, 244, 297 |
| abstract_inverted_index.colistin | 37 |
| abstract_inverted_index.efficacy | 245 |
| abstract_inverted_index.hospital | 277 |
| abstract_inverted_index.in-house | 113 |
| abstract_inverted_index.included | 84 |
| abstract_inverted_index.isolates | 41, 61, 97, 176, 183, 298 |
| abstract_inverted_index.observed | 229 |
| abstract_inverted_index.options. | 282 |
| abstract_inverted_index.positive | 193 |
| abstract_inverted_index.results. | 157 |
| abstract_inverted_index.studies, | 333 |
| abstract_inverted_index.synergy, | 310 |
| abstract_inverted_index.testing, | 56 |
| abstract_inverted_index.available | 314 |
| abstract_inverted_index.challenge | 275 |
| abstract_inverted_index.colistin, | 306 |
| abstract_inverted_index.controls. | 104 |
| abstract_inverted_index.criteria. | 235 |
| abstract_inverted_index.currently | 313 |
| abstract_inverted_index.diffusion | 116 |
| abstract_inverted_index.including | 14 |
| abstract_inverted_index.isolates, | 199 |
| abstract_inverted_index.objective | 17 |
| abstract_inverted_index.performed | 92, 111, 143, 240 |
| abstract_inverted_index.producing | 12 |
| abstract_inverted_index.published | 332 |
| abstract_inverted_index.recovered | 63 |
| abstract_inverted_index.resistant | 269 |
| abstract_inverted_index.settings, | 278 |
| abstract_inverted_index.specimens | 52 |
| abstract_inverted_index.submitted | 53 |
| abstract_inverted_index.treatment | 281, 317 |
| abstract_inverted_index.>CZA/AT | 222 |
| abstract_inverted_index.Importance | 263 |
| abstract_inverted_index.Klebsiella | 45, 270 |
| abstract_inverted_index.Management | 264 |
| abstract_inverted_index.carbapenem | 258 |
| abstract_inverted_index.infections | 266 |
| abstract_inverted_index.inhibitory | 77 |
| abstract_inverted_index.multi-drug | 268 |
| abstract_inverted_index.organisms. | 262 |
| abstract_inverted_index.pneumoniae | 46, 60, 221, 271 |
| abstract_inverted_index.prevalence | 256 |
| abstract_inverted_index.previously | 331 |
| abstract_inverted_index.resistance | 259 |
| abstract_inverted_index.Cefiderocol | 1 |
| abstract_inverted_index.Comparators | 304 |
| abstract_inverted_index.Liofilchem, | 124 |
| abstract_inverted_index.breakpoints | 149 |
| abstract_inverted_index.cefiderocol | 324 |
| abstract_inverted_index.siderophore | 5 |
| abstract_inverted_index.susceptible | 178, 185, 209 |
| abstract_inverted_index.(Liofilchem, | 117 |
| abstract_inverted_index.cefiderocol, | 300 |
| abstract_inverted_index.combination, | 35 |
| abstract_inverted_index.intermediate | 203 |
| abstract_inverted_index.siderophore. | 303 |
| abstract_inverted_index.CZA/aztreonam | 33 |
| abstract_inverted_index.Gram-negative | 10, 261 |
| abstract_inverted_index.approximation | 146 |
| abstract_inverted_index.microdilution | 108, 121 |
| abstract_inverted_index.non-outbreak, | 74 |
| abstract_inverted_index.respectively. | 135, 170, 343 |
| abstract_inverted_index.Identification | 88 |
| abstract_inverted_index.concentration, | 78 |
| abstract_inverted_index.interpretation | 154 |
| abstract_inverted_index.non-duplicate, | 73 |
| abstract_inverted_index.susceptibility | 90, 129, 294 |
| abstract_inverted_index.(bioMérieux). | 95 |
| abstract_inverted_index.carbapenemases, | 13 |
| abstract_inverted_index.standardization. | 114 |
| abstract_inverted_index.Baseline-resistance | 321 |
| abstract_inverted_index.meropenem-resistant | 43 |
| abstract_inverted_index.Meropenem-susceptible | 96 |
| abstract_inverted_index.ceftazidime-avibactam | 31 |
| abstract_inverted_index.ceftazidime-avibactam, | 307 |
| abstract_inverted_index.Clinico-microbiological | 236 |
| abstract_inverted_index.metallo-beta-lactamases. | 15 |
| abstract_inverted_index.ceftazidime-avibactam/aztreonam | 309 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 96 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.46000000834465027 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.65681412 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |